Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

Incidental N2 Nodal Disease and the Heterogeneity of Stage IIIA N2 NSCLC
Thu, 10/30/2008 - 20:50
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Probably the most contentious areas of lung cancer management is stage IIIA NSCLC, with N2 nodal involvement, the nodes outside of the lungs, toward the middle of the chest but on the same side as the main tumor. One of the key issues is that the staging is the same whether there's a single microscopically involved lymph node or multiple enlarged lymph nodes in a few areas of the mediastinum (mid-chest, between the lungs). But the outcomes of these groups of patients is very different, so it may be worth thinking about them a little differently. As shown here, from a retrospective review of just over 700 patients in France who had N2 mediastinal nodes involved (abstract here), outcomes were much better for the subset who had a single lymph node area involved (called a nodal station), and no clinically enlarged nodes (meaning that on a CT scan they didn't appear abnormally big, defined as more than a centimeter):

IIIA N2 heterogeneity Andre (Click to enlarge)

The curves show that the patients with a single (L1 for one level instead of L2 for more than one, in the legend above) non-enlarged (m for microscopic instead of c for clinically involved) nodal area involved have a long-term survival in the range of 35%, while the outcome for patients with visibly enlarged mediastinal nodes and/or more than one level/station involved isn't as favorable, although there are still long-term survivors. But this retrospective series is limited because it pools together people who had differing rigors of staging, some receiving chemo after and some not, and otherwise just a very heterogeneous population. That's somewhat helpful for teasing apart signals within that broad range, but it helps to look at patients treated somewhat uniformly.

We just got some of that information from thoracic surgeons at the University of Alabama, Birmingham, a very respected program led by Dr. Robert Cerfolio. They just published results from their single center experience of 148 patients who had all undergone a chest CT as well as a PET scan and had no findings suggestive of mediastinal involvement. Dr. Cerfolio does a very thorough mediastinal dissection and identified these patients who had been found to have unsuspected mediastinal N2 node involvement, nearly all of whom (93%) subsequently receiving post-operative chemotherapy, and a minority also getting radiation. He reported a 5-year survival of 35% overall, and a more favorable survival among the patients with a single node involved compared with multiple nodes (40% vs. 25%):

Cerfolio unsuspected N2 nodes

Our usual approach if we know someone has stage IIIA NSCLC before surgery is to recommend pre-operative chemotherapy or chemoradiation if we are thinking of pursuing later surgery. But for patients without evidence of nodal disease by careful pre-operative imaging, it's not clear that this is superior to doing surgery and then following with chemo +/- radiation afterward, now that post-operative chemo is a standard approach for higher risk resected patients.

At our institution, we routinely do mediastinoscopies looking for mediastinal node involvement before surgery even in many patients who have completely unremarkably findings in the mediastinum on CT and PET. Uncommonly but not rarely, our surgeon finds a microscopic focus of cancer in 1 or 2 N2 nodes on that mediastinoscopy just before planned surgery. While this has usually led them to stop the procedure, close up, and send them to me for induction (pre-operative, also known as neo-adjuvant) therapy, this work suggests that it's reasonable to proceed with surgery in some cases and pursue the chemo later.

The downside? Some of these patients may not get through it all, such as the 76 year-old otherwise fit man who underwent surgery for an early stage NSCLC tumor who had a single unsuspected node at medistinoscopy, went through surgery, and then saw me for chemo. I recommended and treated him with his first cycle, and even though he did well with it from as far as I could see and measure, he said he wasn't interested in any more treatment. I think he could potentially have done better if he were to have received 3-4 cycles of chemo along with surgery, and maybe he would have been able to do that if we started with chemo and then went on to surgery. But the surgery is the more important and potentially curative treatment here, so it would have been far worse to have had him develop significant problems with pre-operative chemo that kept him from getting surgery, which could cure him even with little or no further therapy.

I'll just close by saying that these concepts all depend on a meticulous per-operative staging workup and a good surgery that removes many lymph nodes. Dr. Cerfolio and the surgeons I work with typically remove a dozen or more nodes, so we can be confident that involvement of no nodes or 1-2 nodes is actually the case. We can presume this if many other nodes have been removed or examined, but if only a handful of nodes were resected, we can't know if there are only a few nodes involved because that's the true extent of disease or because that's all they looked for. Lung surgery is a setting where training, experience, and attention to detail are very critical. When a well-trained lung surgeon finds just a single N2 node involved, those patients can do much better than the general numbers for that stage would suggest.

Next Previous link

Previous PostNext Post

Related Content

Mandarin LCVL
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit:…;  
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Blood Cancer OncTalk
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29